Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unres...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

Quantumup Mar. 17 at 10:10 AM

Stifel reiterated $CYTK Buy; $98, and said::We're reiterating our Buy rating on CYTK ahead of the big 2Q ACACIA readout where we think the trial likely works (POS 70%). $BMY $EWTX $TNYA Here's what else Stifel had to say:: https://x.com/Quantumup1/status/2033847804846576074?s=20

0 · Reply

hobartburns Mar. 17 at 9:23 AM

$BMY Biopharmaceutical company developing innovative medicines for serious diseases

0 · Reply

hogancecillia Mar. 17 at 8:30 AM

$BMY $SNPS $GD $RCL ,,

0 · Reply

DragonAlgo Mar. 17 at 3:24 AM

🐉 $BMY CALL — DragonAlgo® Signal Contract: BMY CALL Expiry: 2026-03-20 | Strike: $60.00 | Type: CALL Option Plan (premium): Entry: $0.66 Stop: $0.47 TP1: $0.85 TP2: $1.11 TP3: $1.57 🔗 https://dragonalgo.com

0 · Reply

taxplanr Mar. 16 at 9:40 PM

Will the road block that has kept the Trump admin from pulling the mRNA bioweapon off the market gotten the message? $BNTX $MRNA $PFE $MRK $BMY

0 · Reply

HedgeFollow Mar. 16 at 5:29 PM

▫️▫️▫️▫️▫️▫️ 🔹 𝗟𝗮𝗿𝗴𝗲 5-𝘀𝘁𝗮𝗿 𝗙𝘂𝗻𝗱 𝗕𝘂𝘆𝘀 in $BMY 🔹 As per latest Q4 filings: • AQR DOUBLED their already big stake. • Two Sigma added 75% more. • Stephen Cohen started a new Large position. They seem to have high confidence in this stock. Source: https://hedgefollow.com/stocks/BMY

0 · Reply

taxplanr Mar. 16 at 2:23 PM

Ivermectin Fenbendazole and Mebendazole curing Pancreatic Cancer $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-a39?utm_source=post-email-title&publication_id=1385328&post_id=191125750&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

EVZ Mar. 16 at 2:17 PM

$BMY Pathetic price movement!

0 · Reply

DragonAlgo Mar. 16 at 12:43 PM

🐉 $BMY CALL — DragonAlgo® Signal Contract: BMY CALL Expiry: 2026-03-20 | Strike: $59.00 | Type: CALL Option Plan (premium): Entry: $0.91 Stop: $0.66 TP1: $1.18 TP2: $1.55 TP3: $2.18 🔗 https://dragonalgo.com

0 · Reply

WallStreetBuyDip Mar. 16 at 7:19 AM

$BMY trading at $59 with volume 50% below average, while $JNJ sitting at $242 with volume 27% below average. JNJ showing stronger price action, but both lacking volume interest. Is the Healthcare sector losing its appeal to traders?

0 · Reply

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Mar 6, 2026, 9:59 PM EST - 10 days ago

U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Mar 2, 2026, 4:16 PM EST - 14 days ago

Bristol Myers Squibb Announces Dividend

Feb 26, 2026, 6:59 AM EST - 18 days ago

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Feb 25, 2026, 8:55 AM EST - 19 days ago

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

Feb 23, 2026, 4:16 PM EST - 21 days ago

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 6:59 AM EST - 21 days ago

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

$U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma$

Feb 17, 2026, 6:59 AM EST - 27 days ago

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Feb 12, 2026, 8:05 AM EST - 4 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Feb 9, 2026, 1:00 AM EST - 5 weeks ago

Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence

Feb 5, 2026, 7:26 PM EST - 5 weeks ago

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

Feb 5, 2026, 12:23 PM EST - 5 weeks ago

Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results

Feb 5, 2026, 10:07 AM EST - 5 weeks ago

Bristol Myers Flags Data-Rich 2026 After Solid Quarter

Feb 5, 2026, 7:17 AM EST - 5 weeks ago

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.

Feb 5, 2026, 7:09 AM EST - 5 weeks ago

Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth

Feb 5, 2026, 7:01 AM EST - 5 weeks ago

Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off

Feb 5, 2026, 6:59 AM EST - 5 weeks ago

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

Feb 4, 2026, 7:00 AM EST - 5 weeks ago

OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb

Feb 4, 2026, 6:59 AM EST - 5 weeks ago

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi

Feb 3, 2026, 6:59 AM EST - 5 weeks ago

Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.

Jan 22, 2026, 2:02 PM EST - 7 weeks ago

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

JANX

Jan 22, 2026, 7:38 AM EST - 7 weeks ago

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

JANX

Jan 21, 2026, 6:17 PM EST - 7 weeks ago

Final Trade: BMY, IGV, SOXX, GEN, AMZN

AMZN SOXX IGV

Jan 20, 2026, 11:00 AM EST - 7 weeks ago

2 Top Blue-Chip Stocks to Buy and Hold in 2026

MSFT

Jan 20, 2026, 8:08 AM EST - 7 weeks ago

Bristol Myers partners with Microsoft for AI-driven lung cancer detection

MSFT

Jan 20, 2026, 6:59 AM EST - 7 weeks ago

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Jan 15, 2026, 4:02 AM EST - 2 months ago

3 Stock Picks Where Technical Indicators Still Say Buy

BURL ITRN

Jan 12, 2026, 6:59 AM EST - 2 months ago

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Jan 9, 2026, 12:57 PM EST - 2 months ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN LLY MRK NVO PFE

Jan 2, 2026, 6:59 AM EST - 2 months ago

Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference

Dec 31, 2025, 7:20 AM EST - 2 months ago

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

CVS PRGO

Dec 27, 2025, 2:30 AM EST - 2 months ago

This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year

Dec 23, 2025, 1:56 PM EST - 2 months ago

Jenny Harrington's top dividend plays for 2026

AMCR ENB VICI

Dec 23, 2025, 11:00 AM EST - 2 months ago

3 Top Value Stocks to Buy and Hold for 2026

CPB STZ

Dec 22, 2025, 6:18 PM EST - 3 months ago

Final Trade: NCNO, LION, SNAP, BMY

NCNO LION SNAP

Dec 19, 2025, 4:09 PM EST - 3 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

GSK MRK AMGN GILD NVS SNY

Dec 19, 2025, 3:14 PM EST - 3 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN GILD GSK MRK NVS SNY

Dec 19, 2025, 3:05 PM EST - 3 months ago

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Dec 19, 2025, 2:34 PM EST - 3 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN GILD GSK MRK NVS SNY

Dec 19, 2025, 10:45 AM EST - 3 months ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN GILD LLY MRK NVO

Dec 18, 2025, 6:59 AM EST - 3 months ago

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

Dec 17, 2025, 4:11 PM EST - 3 months ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN LLY NVS PFE

Dec 16, 2025, 7:04 PM EST - 3 months ago

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

Dec 15, 2025, 6:22 PM EST - 3 months ago

Final Trade: JNJ, NVO, UBER, BMY

JNJ NVO UBER

Dec 15, 2025, 12:56 PM EST - 3 months ago

Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored

Dec 11, 2025, 6:59 AM EST - 3 months ago

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

Dec 10, 2025, 4:16 PM EST - 3 months ago

Bristol Myers Squibb Announces Dividend Increase

Dec 9, 2025, 7:00 AM EST - 3 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BNTX

Dec 8, 2025, 4:30 PM EST - 3 months ago

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

$Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)$

Dec 4, 2025, 8:15 PM EST - 3 months ago

Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Quantumup Mar. 17 at 10:10 AM

0 · Reply

hobartburns Mar. 17 at 9:23 AM

$BMY Biopharmaceutical company developing innovative medicines for serious diseases

0 · Reply

hogancecillia Mar. 17 at 8:30 AM

$BMY $SNPS $GD $RCL ,,

0 · Reply

DragonAlgo Mar. 17 at 3:24 AM

0 · Reply

taxplanr Mar. 16 at 9:40 PM

Will the road block that has kept the Trump admin from pulling the mRNA bioweapon off the market gotten the message? $BNTX $MRNA $PFE $MRK $BMY

0 · Reply

HedgeFollow Mar. 16 at 5:29 PM

0 · Reply

taxplanr Mar. 16 at 2:23 PM

0 · Reply

EVZ Mar. 16 at 2:17 PM

$BMY Pathetic price movement!

0 · Reply

DragonAlgo Mar. 16 at 12:43 PM

0 · Reply

WallStreetBuyDip Mar. 16 at 7:19 AM

0 · Reply

taxplanr Mar. 15 at 1:57 PM

Peer reviewed study finds mRNA alters genes causing uniniended gene expressions $BNTX $MRNA $MRK $BMY Uncontrollable platform https://aapsonline.org/covid-mrna-vaccines-may-alter-gene-expression-according-to-journal-of-american-physicians-and-surgeons/

0 · Reply

DragonAlgo Mar. 13 at 11:50 PM

🐉 $BMY CALL — DragonAlgo® Signal Contract: BMY CALL Expiry: 2026-03-20 | Strike: $55.00 | Type: CALL Option Plan (premium): Entry: $4.15 Stop: $2.99 TP1: $5.40 TP2: $7.06 TP3: $9.96 🔗 https://dragonalgo.com

0 · Reply

taxplanr Mar. 13 at 2:00 PM

There won't be a cancer market left for $BNTX $MRNA $BMY $MRK https://stocktwits.com/news-articles/markets/equity/why-ibrx-rising-today-nk-cell-therapy-update/cZdDfe3RIas

1 · Reply

DragonAlgo Mar. 13 at 8:32 AM

🐉 $BMY CALL — DragonAlgo® Signal Contract: BMY CALL Expiry: 2026-03-13 | Strike: $59.00 | Type: CALL Option Plan (premium): Entry: $0.22 Stop: $0.16 TP1: $0.29 TP2: $0.37 TP3: $0.53 🔗 https://dragonalgo.com

0 · Reply

Chemaster Mar. 13 at 4:01 AM

$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/

0 · Reply

truehealthvalue Mar. 12 at 9:26 PM

$BMY take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

DragonAlgo Mar. 12 at 8:12 PM

🐉 $BMY CALL — DragonAlgo® Signal Contract: BMY CALL Expiry: 2026-03-20 | Strike: $60.00 | Type: CALL Option Plan (premium): Entry: $0.76 Stop: $0.55 TP1: $0.99 TP2: $1.29 TP3: $1.82 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

ZacksResearch Mar. 12 at 4:21 PM

$BMY’s pipeline is deep and promising — are you ready for the upside? 🚀 💊 Positive phase III SUCCESSOR-2 study for mezigdomide in RRMM 🤝 Milvexian partnership with $JNJ to redefine anticoagulant therapy 🔍 Valuation: Trading at 9.64x forward earnings vs. industry’s 17.99x Opportunity assessment here 👉 https://www.zacks.com/stock/news/2883253/is-bristol-myers-deep-pipeline-the-key-to-future-growth?cid=sm-stocktwits-2-2883253-body-37176&ADID=SYND_STOCKTWITS_TWEET_2_2883253_BODY_37176

0 · Reply

ZacksResearch Mar. 12 at 3:21 PM

$BMY betting big on its pipeline — could the next wave of drugs drive the next growth cycle? 🧪 The company highlights multiple late-stage candidates and registrational data expected in 2026, reinforcing confidence in its next-gen CELMoD program. See what could shape the company’s next phase of growth 👉 https://www.zacks.com/stock/news/2883253/is-bristol-myers-deep-pipeline-the-key-to-future-growth?cid=sm-stocktwits-2-2883253-teaser-37175&ADID=SYND_STOCKTWITS_TWEET_2_2883253_TEASER_37175

0 · Reply

taxplanr Mar. 12 at 2:54 PM

Did you know the CIA has known since 1951 that dewormers fight cancer? $BNTX $MRNA $BMY $MRK https://www.msn.com/en-us/health/other/cia-faces-furious-backlash-after-hidden-document-hints-at-possible-cancer-cure/ar-AA1XQBYt

0 · Reply

TheTradingAnalyst Mar. 12 at 5:36 AM

$BMY with a bullish setup... $SPX $SPY $QQQ Nice setup. Great opportunity to participate in the next up leg. Good luck. Real-time alerts at http://thetradinganalyst.com

0 · Reply

DragonAlgo Mar. 12 at 2:20 AM

🐉 $BMY CALL — DragonAlgo® Signal Contract: BMY CALL Expiry: 2026-03-20 | Strike: $60.00 | Type: CALL Option Plan (premium): Entry: $1.12 Stop: $0.81 TP1: $1.46 TP2: $1.90 TP3: $2.69 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Market Cap	120.31B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.61
Forward PE	9.41
Profit Margin	14.64%
Debt to Equity Ratio	2.44

Volume	8,436,800
Avg Vol	12,914,616
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	33%
Beta	0.26
Analysts	Sell
Price Target	$62.15